Skip to main content
Erschienen in: World Journal of Urology 4/2009

01.08.2009 | Review

The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates

verfasst von: Mark H. Katz, Scott E. Eggener

Erschienen in: World Journal of Urology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Over the past century, retroperitoneal lymph node dissection (RPLND) for patients with non-seminomatous germ cell tumors has evolved to become an indispensable diagnostic and therapeutic procedure. Bilateral RPLND with inclusion of the suprahilar regions initially established therapeutic efficacy but was associated with significant ejaculatory morbidity. Decades later, multiple anatomic mapping studies demonstrated a predilection for low-volume retroperitoneal metastases to be ipsilateral and infrahilar, leading to the introduction and popularity of several modified templates. By minimizing contralateral dissection and avoiding essential neural pathways, coordinated antegrade ejaculation rates improved considerably. Simultaneously, prospective nerve-sparing techniques were developed to preserve sympathetic nerve function, allowed for modified or bilateral templates, and resulted in minimal ejaculatory morbidity. The primary oncologic concern with modified templates remains the potential for unresected ‘extra-template’ disease leading to retroperitoneal or systemic recurrences requiring additional therapy. While modified templates continue to be widely used, larger scale and longer-term studies are essential to fully elucidate their appropriate application and therapeutic efficacy.
Literatur
1.
Zurück zum Zitat Stimson JC (1897) A new operation for teratoma testis. Med Rec NY 3:623 Stimson JC (1897) A new operation for teratoma testis. Med Rec NY 3:623
3.
Zurück zum Zitat Hinman F (1914) The operative treatment of tumors of the testicle. JAMA 63:2009–2015 Hinman F (1914) The operative treatment of tumors of the testicle. JAMA 63:2009–2015
4.
Zurück zum Zitat Patton JF, Hewitt CB, Mallis N (1959) Diagnosis and treatment of tumors of the testis. JAMA 171:2194–2198 Patton JF, Hewitt CB, Mallis N (1959) Diagnosis and treatment of tumors of the testis. JAMA 171:2194–2198
6.
Zurück zum Zitat Ray B, Jewett MA, Donohue RE (1997) Summary of distribution of retroperitoneal lymph node metastases in testicular germinal tumors (by Biswamay Ray, MD, Steven I. Hajdu, MD, and Willet F. Whitmore, Jr, MD) 1974. Semin Urol Oncol 15:130–135PubMed Ray B, Jewett MA, Donohue RE (1997) Summary of distribution of retroperitoneal lymph node metastases in testicular germinal tumors (by Biswamay Ray, MD, Steven I. Hajdu, MD, and Willet F. Whitmore, Jr, MD) 1974. Semin Urol Oncol 15:130–135PubMed
7.
Zurück zum Zitat Donohue JP, Zachary JM, Maynard BR (1982) Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128:315–320PubMed Donohue JP, Zachary JM, Maynard BR (1982) Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128:315–320PubMed
9.
Zurück zum Zitat Weissbach L, Boedefeld EA (1987) Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138:77–82PubMed Weissbach L, Boedefeld EA (1987) Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138:77–82PubMed
10.
Zurück zum Zitat Lange PH, Narayan P, Fraley EE (1984) Fertility issues following therapy for testicular cancer. Semin Urol 2:264–274PubMed Lange PH, Narayan P, Fraley EE (1984) Fertility issues following therapy for testicular cancer. Semin Urol 2:264–274PubMed
11.
12.
Zurück zum Zitat Pizzocaro G, Salvioni R, Zanoni F (1985) Unilateral lymphadenectomy in intraoperative stage I nonseminomatous germinal testis cancer. J Urol 134:485–489PubMed Pizzocaro G, Salvioni R, Zanoni F (1985) Unilateral lymphadenectomy in intraoperative stage I nonseminomatous germinal testis cancer. J Urol 134:485–489PubMed
13.
Zurück zum Zitat Stephenson AJ, Bosl GJ, Motzer RJ et al (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23:2781–2788. doi:10.1200/JCO.2005.07.132 PubMedCrossRef Stephenson AJ, Bosl GJ, Motzer RJ et al (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23:2781–2788. doi:10.​1200/​JCO.​2005.​07.​132 PubMedCrossRef
14.
Zurück zum Zitat Richie JP (1990) Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 144:1160–1163PubMed Richie JP (1990) Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 144:1160–1163PubMed
15.
Zurück zum Zitat Doerr A, Skinner EC, Skinner DG (1993) Preservation of ejaculation through a modified retroperitoneal lymph node dissection in low stage testis cancer. J Urol 149:1472–1474PubMed Doerr A, Skinner EC, Skinner DG (1993) Preservation of ejaculation through a modified retroperitoneal lymph node dissection in low stage testis cancer. J Urol 149:1472–1474PubMed
16.
Zurück zum Zitat Weissbach L, Boedefeld EA, Horstmann-Dubral B (1990) Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Final results of a prospective multicenter trial 1982–1987. Testicular Tumor Study Group. Eur Urol 17:97–106PubMed Weissbach L, Boedefeld EA, Horstmann-Dubral B (1990) Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Final results of a prospective multicenter trial 1982–1987. Testicular Tumor Study Group. Eur Urol 17:97–106PubMed
17.
Zurück zum Zitat Jewett MA, Kong YS, Goldberg SD et al (1988) Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 139:1220–1224PubMed Jewett MA, Kong YS, Goldberg SD et al (1988) Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 139:1220–1224PubMed
18.
Zurück zum Zitat Donohue JP, Foster RS, Rowland RG et al (1990) Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144:287–291PubMed Donohue JP, Foster RS, Rowland RG et al (1990) Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144:287–291PubMed
20.
Zurück zum Zitat Carver BS, Shayegan B, Eggener SE et al (2007) Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25:4365–4369. doi:10.1200/JCO.2007.11.2078 PubMedCrossRef Carver BS, Shayegan B, Eggener SE et al (2007) Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25:4365–4369. doi:10.​1200/​JCO.​2007.​11.​2078 PubMedCrossRef
22.
24.
27.
Zurück zum Zitat Baniel J, Foster RS, Gonin R et al (1995) Late relapse of testicular cancer. J Clin Oncol 13:1170–1176PubMed Baniel J, Foster RS, Gonin R et al (1995) Late relapse of testicular cancer. J Clin Oncol 13:1170–1176PubMed
Metadaten
Titel
The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates
verfasst von
Mark H. Katz
Scott E. Eggener
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 4/2009
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-009-0407-z

Weitere Artikel der Ausgabe 4/2009

World Journal of Urology 4/2009 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.